Septerna, Inc. (SEPN)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$40.41-1.15%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Septerna, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	22M
EPS	—	-0.448
Annual ending 2026-12-31
Revenue	—	96.04M
EPS	—	-1.35
Annual ending 2027-12-31
Revenue	—	73.62M
EPS	—	-2.278

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash runway supports operations at least through 2029	The company plans to fund operations through 2029.	Intact	Cash runway falls short of supporting operations into 2029	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Cash, cash equivalents, and marketable securities were $522.1M in 2026-Q1 and $516.5M in 2026-Q2, supporting management's claim of runway into 2029. The slight decrease reflects ongoing operations but the cash position remains strong, consistent with management's stated priority. Delivery assessment Oct 24, 2026
Revenue from Novo Nordisk collaboration reaches at least $26.5 million in Q1 2026	Septerna grows revenue from its Novo Nordisk deal to $26.5 million in Q1 2026.	Improving	Revenue from Novo Nordisk falls below $21.5 million in Q1 2026	Revenue: $26.746M FY2026-Q2; GAAP. Published target: >= 26.5 USD_MILLIONS. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 10, 202626,746,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: cb3526b6-a8f2-4a78-a4b6-243e5080beb8. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Revenue from the Novo Nordisk collaboration increased from $24.1M in 2025-Q4 to $26.7M in 2026-Q2, showing growth consistent with management's stated priority. This reflects ongoing milestone and research service revenue contributions. Delivery assessment Oct 24, 2026
Advance SEP-631 into Phase 2 development	It advances its drug SEP-631 into Phase 2 trials.	Improving	SEP-631 development stalls before or during Phase 2 trials	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.28

$-2.39 → $-2.28 · observed estimates

FY2027 revenue$0.07B

$0.07B → $0.07B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.39	$65,849,999	7 / 7
2026-07-25	$-2.39	$65,849,999	7 / 7
2026-07-26	$-2.39	$65,849,999	7 / 7
2026-07-27	$-2.66	$65,833,550	5 / 10
2026-07-28	$-2.66	$65,833,550	5 / 10
2026-07-29	$-2.66	$65,833,550	5 / 10
2026-07-30	$-2.66	$65,833,550	5 / 10
2026-07-31	$-2.39	$65,849,999	7 / 7
2026-08-01	$-2.39	$65,849,999	7 / 7
2026-08-02	$-2.66	$65,833,550	5 / 10
2026-08-03	$-2.66	$65,833,550	5 / 10
2026-08-04	$-2.39	$65,819,999	7 / 7
2026-08-05	$-2.66	$65,833,550	5 / 10
2026-08-06	$-2.39	$65,819,999	7 / 7
2026-08-08	$-2.39	$65,819,999	7 / 7
2026-08-09	$-2.66	$65,833,550	5 / 10
2026-08-10	$-2.39	$65,819,999	7 / 7
2026-08-12	$-2.39	$65,819,999	7 / 7
2026-08-13	$-2.39	$65,819,999	7 / 7
2026-08-14	$-2.39	$65,819,999	7 / 7
2026-08-15	$-2.39	$65,819,999	7 / 7
2026-08-16	$-2.39	$65,819,999	6 / 7
2026-08-17	$-2.39	$65,819,999	6 / 7
2026-08-18	$-2.39	$65,819,999	6 / 7
2026-08-19	$-2.39	$65,819,999	6 / 7
2026-08-20	$-2.28	$73,620,000	7 / 7
2026-08-21	$-2.28	$73,620,000	7 / 7
2026-08-22	$-2.28	$73,620,000	7 / 7
2026-08-23	$-2.28	$73,620,000	7 / 7
2026-08-24	$-2.28	$73,620,000	7 / 7
2026-08-25	$-2.28	$73,620,000	7 / 7
2026-08-26	$-2.28	$73,620,000	7 / 7
2026-08-27	$-2.28	$73,620,000	7 / 7
2026-08-28	$-2.28	$73,620,000	7 / 7
2026-08-29	$-2.28	$73,620,000	7 / 7
2026-08-30	$-2.28	$73,620,000	7 / 7
2026-08-31	$-2.28	$73,620,000	7 / 7
2026-09-01	$-2.28	$73,620,000	7 / 7
2026-09-02	$-2.28	$73,620,000	7 / 7
2026-09-03	$-2.28	$73,620,000	7 / 7
2026-09-04	$-2.28	$73,620,000	7 / 7
2026-09-05	$-2.28	$73,620,000	7 / 7
2026-09-06	$-2.28	$73,620,000	7 / 7
2026-09-07	$-2.28	$73,620,000	7 / 7
2026-09-08	$-2.28	$73,620,000	7 / 7
2026-09-09	$-2.28	$73,620,000	7 / 7
2026-09-10	$-2.28	$73,620,000	7 / 7
2026-09-11	$-2.28	$73,620,000	7 / 7
2026-09-12	$-2.28	$73,620,000	7 / 7
2026-09-13	$-2.28	$73,620,000	7 / 7
2026-09-14	$-2.28	$73,620,000	7 / 7
2026-09-15	$-2.28	$73,620,000	7 / 7
2026-09-16	$-2.28	$73,620,000	7 / 7
2026-09-17	$-2.28	$73,620,000	7 / 7
2026-09-18	$-2.28	$73,620,000	7 / 7
2026-09-19	$-2.28	$73,620,000	7 / 7
2026-09-20	$-2.28	$73,620,000	7 / 7
2026-09-21	$-2.28	$73,620,000	7 / 7
2026-09-22	$-2.28	$73,620,000	7 / 7
2026-09-23	$-2.28	$73,620,000	7 / 7
2026-09-24	$-2.28	$73,620,000	7 / 7
2026-09-25	$-2.28	$73,620,000	7 / 7
2026-09-26	$-2.28	$73,620,000	7 / 7
2026-09-27	$-2.28	$73,620,000	7 / 7
2026-09-28	$-2.28	$73,620,000	7 / 7
2026-09-29	$-2.28	$73,620,000	7 / 7
2026-09-30	$-2.28	$73,620,000	7 / 7
2026-10-01	$-2.28	$73,620,000	7 / 7
2026-10-02	$-2.28	$73,620,000	7 / 7
2026-10-03	$-2.28	$73,620,000	7 / 7
2026-10-04	$-2.28	$73,620,000	7 / 7
2026-10-05	$-2.28	$73,620,000	7 / 7
2026-10-06	$-2.28	$73,620,000	7 / 7
2026-10-07	$-2.28	$73,620,000	7 / 7
2026-10-08	$-2.28	$73,620,000	7 / 7
2026-10-09	$-2.28	$73,620,000	7 / 7
2026-10-10	$-2.28	$73,620,000	7 / 7
2026-10-11	$-2.28	$73,620,000	7 / 7
2026-10-12	$-2.28	$73,620,000	7 / 7
2026-10-13	$-2.28	$73,620,000	7 / 7
2026-10-14	$-2.28	$73,620,000	7 / 7
2026-10-15	$-2.28	$73,620,000	7 / 7
2026-10-16	$-2.28	$73,620,000	7 / 7
2026-10-17	$-2.28	$73,620,000	7 / 7
2026-10-18	$-2.28	$73,620,000	7 / 7
2026-10-19	$-2.28	$73,620,000	7 / 7
2026-10-20	$-2.28	$73,620,000	7 / 7
2026-10-21	$-2.28	$73,620,000	7 / 7
2026-10-22	$-2.28	$73,620,000	7 / 7
2026-10-23	$-2.28	$73,620,000	7 / 7
2026-10-24	$-2.28	$73,620,000	7 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	9	0	0
2026-06-01	10	0	0
2026-07-01	10	0	0
2026-08-01	10	0	0
2026-09-01	10	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash runway supports operations at least through 2029Direct metric needs a verified mapping
Revenue from Novo Nordisk collaboration reaches at least $26.5 million in Q1 2026Revenue: $26.746M
Advance SEP-631 into Phase 2 developmentDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-26.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Septerna, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder: it is loss-making, with elevated risk and weak recent financial performance. The thesis is in a watch state, with muted price reaction and medium overall evidence confidence.

What's priced into Septerna, Inc.

SEPN is tagged as stretched, with a modeled premium of about two times peers and a durable-premium rationale; confidence in that valuation model is low. The expectations gap is 0.22, but the evidence does not say exactly what growth the market assumes.

What the fundamentals likely do

Near term, the three recent earnings beats are positive, but recent financial performance remains well below the industry cohort and the business is still loss-making. Management is advancing SEP-479, with data expected in early 2027, and plans Phase 2b trials for SEP-631 in the second half of 2026; cash and marketable securities support a stated runway into 2029, though the balance edged lower in the latest quarter.

What Septerna, Inc. hinges on

The multi-year thesis hinges on clinical progress and maintaining the cash runway, especially as SEP-479 data approach and SEP-631 advances toward planned trials. Near-term risks include a guidance cut and weakening jobs data, while continued strength from major Healthcare companies could support sector momentum; the sector backdrop has recently improved.